← ANALYST RATINGS · TIPRANKS

Orasure Technologies (OSUR): analyst forecast and price target

$3.61 −5.25% close 16.10.26 · market cap $263M · Healthcare · Medical - Instruments & Supplies IWM 0.01%
Price targets and ratings of

Analyst consensus

0 Buy0 Hold0 Sell

Ratings of 0 analysts in the last 3 months · top analysts only

12-month forecast

—— upside

Based on 0 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $3.61.

$2.00$3.00$4.00Jan 26AprJulOctJan 27AprJulOct
Highest target — Average target — Lowest target —
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Recommendation trend · top analysts

00001Oct 25NovDecJan 26FebMarAprMayJunJulAugSepOct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy000000
Buy000000
Hold000000
Sell000000

Earnings and sales forecast

Next report: 10.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.23 (from $-0.23 to $-0.23). Last quarter: $0.09.

Sales

Next quarter’s sales estimate — $31M (from $31M to $31M). Last quarter: $31M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Orasure Technologies
  • CEO: Carrie Eglinton Manner
  • Employees: 500
  • 220 East First Street, Bethlehem, PA, 18015, US
  • www.orasure.com

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distr

Data from the stock’s TipRanks forecast page, read 184 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗